You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CpG 7909

Showing 1 - 25 of 135
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cancer, Tumor Trial in Frankfurt (NY-ESO-1b peptide plus CpG 7909 and Montanide® ISA-51)

Completed
Has Results
  • Cancer
  • Neoplasm
  • NY-ESO-1b peptide plus CpG 7909 and Montanide® ISA-51
  • Frankfurt, Germany
    Krankenhaus Nordwest
Oct 3, 2022

Malignant Melanoma Trial in Brussels (MAGE-3.A1 peptide and CpG 7909)

Terminated
Has Results
  • Malignant Melanoma
  • MAGE-3.A1 peptide and CpG 7909
  • Brussels, Belgium
  • +1 more
Aug 2, 2021

Tumors Trial in New York (NY-ESO-1 Protein Vaccine)

Completed
Has Results
  • Tumors
  • NY-ESO-1 Protein Vaccine
  • New York, New York
  • +1 more
Nov 29, 2021

Prostate Cancer Trial in Frankfurt, Zurich (NY-ESO-1 protein/CpG 7909)

Completed
Has Results
  • Prostate Cancer
  • NY-ESO-1 protein/CpG 7909
  • Frankfurt, Germany
  • +1 more
Jan 7, 2021

Minimal Residual Disease, KRAS G12D, KRAS G12R Trial in United States (ELI-002 2P)

Recruiting
  • Minimal Residual Disease
  • +11 more
  • ELI-002 2P
  • Duarte, California
  • +10 more
Jan 18, 2023

Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, NSCLC Trial (ELI-002 7P)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • +14 more
  • ELI-002 7P
  • (no location specified)
Feb 3, 2023

Anthrax Trial in United States (BioThrax, AV7909, Sodium chloride injection USP, 0.9% ())

Completed
Has Results
  • Anthrax
  • BioThrax
  • +2 more
  • Lenexa, Kansas
  • +3 more
Jul 13, 2020

Malaria Trial in Baltimore, Bamako (BSAM2/Alhydrogel + CPG 7909)

Completed
  • Malaria
  • BSAM2/Alhydrogel + CPG 7909
  • Baltimore, Maryland
  • +1 more
Dec 14, 2019

Lymphoma, Mantle-Cell Trial in Stanford (biological, procedure, drug)

Completed
Has Results
  • Lymphoma, Mantle-Cell
  • CpG-MCL vaccine
  • +7 more
  • Stanford, California
    Stanford University Medical Center
Jan 8, 2020

Anthrax Trial in United States (AV7909 Full Dose (0.5 mL), AV7909 Half Dose (0.25 mL))

Not yet recruiting
  • Anthrax
  • AV7909 Full Dose (0.5 mL)
  • AV7909 Half Dose (0.25 mL)
  • Hickory, North Carolina
  • +6 more
Aug 10, 2023

Anthrax, Anthrax Immunisation Trial in Baltimore (AV7909)

Not yet recruiting
  • Anthrax
  • Anthrax Immunisation
  • AV7909
  • Baltimore, Maryland
  • +1 more
Apr 7, 2022

SARS-CoV-2 Infection Trial in Australia (ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001))

Recruiting
  • SARS-CoV-2 Infection
  • ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001)
  • Kanwal, New South Wales, Australia
  • +5 more
Nov 16, 2022

Tuberculosis Trial in Shanghai (Placebo, Low dose adjuvant, High dose adjuvant)

Completed
  • Tuberculosis
  • Placebo
  • +4 more
  • Shanghai, Shanghai, China
    Shanghai Public Health clinical Center
Mar 9, 2022

Anthrax Trial in United States (Ciprofloxacin 500Mg Tablet, Doxycycline 100Mg Tablet, AV7909)

Completed
Has Results
  • Anthrax
  • Ciprofloxacin 500Mg Tablet
  • +2 more
  • DeLand, Florida
  • +3 more
Nov 9, 2021

Anthrax Trial in United States (AV7909, BioThrax)

Completed
Has Results
  • Anthrax
  • AV7909
  • BioThrax
  • Birmingham, Alabama
  • +34 more
Nov 21, 2021

Effectiveness of Standard Therapy of Acne Vulgaris

Completed
  • Acne Vulgaris
    • Jakarta Pusat, Jakarta, Indonesia
      dr.Cipto Mangunkusumo National Central General Hospital
    Aug 7, 2023

    Pain, Dementia Trial (Pain-CPG-EIT, Pain-CPG-Education Only)

    Not yet recruiting
    • Pain
    • Dementia
    • Pain-CPG-EIT
    • Pain-CPG-Education Only
    • (no location specified)
    May 12, 2023

    Healthcare Worker, Hepatitis B Vaccine, Nonresponder Trial in Madison (Recombinant hepatitis B vaccine with CpG adjuvant)

    Recruiting
    • Healthcare Worker, Hepatitis B Vaccine, Nonresponder
    • Recombinant hepatitis B vaccine with CpG adjuvant
    • Madison, Wisconsin
      University of Wisconsin
    Jul 5, 2022

    Clinical Practice Guidelines, Lower Limb Amputation Above Knee (Injury), Lower Limb Amputation Below Knee (Injury) Trial in

    Completed
    • Clinical Practice Guidelines
    • +7 more
    • Telehealth-based strategy
    • Medellín, Antioquia, Colombia
      Universidad de Antioquia
    Nov 2, 2022

    Melanoma Trial in Lausanne, Geneva (Melan-A ELA + Montanide, Melan-A ELA + NY-ESO-1b + MAGE-A10 + Montanide, Melan-A -ELA +

    Completed
    Has Results
    • Melanoma
    • Melan-A ELA + Montanide
    • +4 more
    • Lausanne, Vaud, Switzerland
    • +1 more
    Jun 2, 2020

    Hepatitis B Trial in Baltimore, Falls Church (Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B])

    Withdrawn
    • Hepatitis B
    • Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B]
    • Baltimore, Maryland
    • +1 more
    Jul 19, 2022

    Plague, Pneumonic, Plague, Vaccine-Preventable Diseases Trial in United States (rF1V vaccine and CpG 1018® adjuvant, rF1V

    Recruiting
    • Plague, Pneumonic
    • +2 more
    • rF1V vaccine and CpG 1018® adjuvant
    • rF1V vaccine
    • Huntsville, Alabama
    • +4 more
    Aug 16, 2022

    Low-Grade B-cell Lymphoma Trial in New York (rhuFlt3L/CDX-301, Poly-ICLC)

    Recruiting
    • Low-Grade B-cell Lymphoma
    • New York, New York
      Icahn School of Medicine at Mount Sinai
    Nov 17, 2020

    Covid19 Trial in Canada, United States (Low Dose of KBP-COVID-19, High Dose of KBP-COVID-19, Placebo)

    Active, not recruiting
    • Covid19
    • Low Dose of KBP-COVID-19
    • +2 more
    • West Palm Beach, Florida
    • +7 more
    Aug 15, 2022

    Myeloid Malignancies, Lymphoid Malignancies Trial in Durham (NK Cell enriched-DLI only, NK-DLI + DUK-CPG-001)

    Recruiting
    • Myeloid Malignancies
    • Lymphoid Malignancies
    • NK Cell enriched-DLI only
    • NK-DLI + DUK-CPG-001
    • Durham, North Carolina
      Duke University Health System
    Mar 8, 2022